China FDA changes will speed up approval process, says CRO

By Flora Southey

- Last updated on GMT

Four new draft policies were released May 11. (Image: iStock/Golden_Brown)
Four new draft policies were released May 11. (Image: iStock/Golden_Brown)

Related tags: Clinical trial

Proposed changes to drug, medical device and clinical testing regulations provide stimulus for conducting trials in China, says CRO George Clinical.

The contract research organisation’s (CRO) managing director, Philip Gregory, said the China Food and Drug Administration’s (CFDA) four new draft policies​ (in Chinese), released May 11, herald an exciting new era for drug and device development.

“If implemented in full, these proposed changes will standardise regulatory requirements, allow for greater use of foreign data broadening eligibility of sites to conduct trials, provide greater transparency of the ethics processes, and ultimately shorten approval timelines,” ​he said.

According to the China-based director, the policies support investigators and clinical testing organisations to carry out clinical trials, improve the clinical trial review process, accept overseas clinical trial data, and support exploratory clinical research, which, if approved, will make the CFDA regulations comparable with other major global players.

The proposed changes show a “proactive response by a regulatory body keen to improve the overall drug development process and make new medicines available faster for the Chinese population,” ​he said.

The draft policies – open for public comment until June 10 – highlight Chinese regulators’ continued commitment to improving access to medicines.

The CFDA released proposed changes​ to drug trial and API importation laws on March 17 to shorten clinical trials and approval times to meet “public demand for new drugs.” 

Related news

Show more

Related products

show more

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars